Glucarpidase

CHEMBL1863515 Phase 4 Onaylandı Enzyme
Half-Life
Bioavailability
Protein Binding
Molecular Weight
261.5 g/mol
LogP
Phase
4

A recombinant enzyme that rapidly degrades methotrexate in the blood, used to treat toxic methotrexate levels in patients with delayed drug clearance due to kidney dysfunction. It provides an immediate rescue when methotrexate accumulates to dangerous concentrations following high-dose chemotherapy. This enzyme cleaves methotrexate into inactive metabolites, protecting patients from potentially fatal toxicity.

Moleküler Ağırlık

261,5000 g/mol

TPSA

0,00 Ų

Terapötik Alanlar

Etki Mekanizması

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

[Zn+2].[Zn+2].[Zn+2].[Zn+2]

InChI

InChI=1S/4Zn/q4*+2

Molecular Formula

Zn4+8

HBD / HBA

- / -

Döndürülebilir Bağlar

0

Ağır Atomlar

4

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A recombinant enzyme that rapidly degrades methotrexate in the blood, used to treat toxic methotrexate levels in patients with delayed drug clearance due to kidney dysfunction. It provides an immediate rescue when methotrexate accumulates to dangerous concentrations following high-dose chemotherapy. This enzyme cleaves methotrexate into inactive metabolites, protecting patients from potentially fatal toxicity.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Glucarpidase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1863515. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 21195079. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.